Navigation Links
Abbott Statement: Abbott Provides Support for Cholera Relief Efforts in Haiti
Date:10/27/2010

Haiti relief efforts build on Abbott's existing philanthropic partnerships to expand access to health care in the country.  Since 2007, Abbott and the Abbott Fund have provided more than $34 million in grants and product donations to help address health needs in Haiti, including maternal and child health, diabetes, HIV/AIDS and malnutrition.

Pre-Positioned Abbott Products Supported Early Relief Efforts

Abbott products were in use immediately following the earthquake in Haiti.  Last year, Abbott worked with Direct Relief International to strategically pre-position essential products in Haiti to prepare for potential natural disasters.  As a result of this work, several health centers in Haiti were able to provide an initial quantity of Abbott rehydration solutions, antibiotics and nutritional products to people in need following the earthquake.

Video of Abbott products being packed by Direct Relief International for use in Haiti is available at http://agendanyc.com/clients/abbott/preparedness.htm.  Filmed in mid-2009, this footage highlights ongoing efforts to pre-position aid.

About Abbott and the Abbott Fund

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacturing and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's website at www.abbott.com.

The Abbott Fund is a philanthropic foundation established by Abbott in 1951.  The Abbott Fund's mission is to create healthier global communities by investing in creative ideas that promote science, expand access to health care and strengthen communities worldwide.  For more information on the Abbott Fund, visit www.abbottfund.org.


'/>"/>
SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- , , Marks E-QURE , ... distribution agreement, following similar agreements in Israel and ... 5 billion global market ... a leader in medical devices for the treatment of advanced wound care, announced ... (TeckMedica) in Colombia for the Company,s patented Bio-electrical Signal ...
(Date:1/19/2017)... YORK , Jan. 18, 2017 The ... 1,669.40 billion by 2021 from USD 1,179.20 billion in ... period. Increasing prevalence of chronic diseases, increasing demand ... the factors driving the growth of this market. Whereas, ... and generic drugs offer significant growth opportunities for players ...
(Date:1/18/2017)... PORTLAND, Oregon and PUNE, India ... report published by Allied Market Research, titled, "Breast Imaging Technologies ... projects that the global breast imaging technologies market size was ... reach $4,502 million by 2022, growing at a CAGR of ... and Europe together accounted for ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... ... which serves Lawrenceville, New Jersey and the surrounding area, is inaugurating a ... sclerosis (ALS), more commonly known as Lou Gehrig's disease or motor neurone disease, ...
(Date:1/19/2017)... Angeles, CA (PRWEB) , ... January 18, 2017 , ... ... hazards while driving during a rain storm by slowing down and increasing the space ... on Fox 40. Los Angeles based car accident attorney Raymond R. Hassanlou notes that, ...
(Date:1/19/2017)... ... January 19, 2017 , ... "ProParagraph Basics ... simplify the editing process for all media productions," said Christina Austin - CEO ... 30 simplistically styled self-animating paragraphs designed for multi-lined text purposes. Choose from ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting of a ... about the benefits of fidgeting to relieve stress and anxiety. No one was ... Think Ink Pen had just completed a successful Kickstarter campaign raising $67,000 on the ...
(Date:1/18/2017)... Calif, USA; and SHANGHAI, China – , ... ... 2017 -- Global public health organization NSF International has certified ... arsenic) to NSF/ANSI 53: Drinking Water Treatment Units – Health ... This certification verifies that MicroCeramics’ NanoNose Pitcher Filter System filters ...
Breaking Medicine News(10 mins):